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Background: Substantial advances have been generated in understanding the pathogenesis of rheumatoid arthritis
(RA). Current murine models of RA-like disease have provided great insights into the molecular mechanism of
inflammatory arthritis due to the use of genetically deficient or transgenic mice. However, these studies are limited
by differences that exist between human and murine immune systems. Thus, the development of an animal model
that utilizes human immune cells, will afford the opportunity to study their function in the initiation and
propagation of inflammatory arthritis.
Methods: One to two-day old irradiated NOD-scid IL2rγnull (NSG) mice were reconstituted with human CD34+ cord
blood stem cells. Leukocytes were analyzed by flow cytometry and circulating antibodies were determined by
ELISA. Arthritis was induced by injecting complete Freund’s adjuvant into knee or ankle joints. Mice were also
treated with the TNF inhibitor, Etanercept, or PBS and joints were analyzed histologically.
Results: Humanized mice were established with high reconstitution rates and were able to spontaneously produce
human immunoglobulins as well as specific IgG in response to immunization. Intraperitoneal injection of
thioglycolate or injection of complete Freund’s adjuvant into joints resulted in migration of human immune cells to
the injected sites. Arthritic humanized mice treated with Etanercept had markedly less inflammation, which was
associated with decreased total numbers of human CD45+ cells, including human lymphocytes and neutrophils.
Conclusions: The humanized mouse model is a new model to study inflammatory arthritis disease using human
leukocytes without rejection of engrafted tissue. Future studies may adapt this system to incorporate RA patient
cord blood and develop a chimeric animal model of inflammatory arthritis using genetically predisposed immune
cells.
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Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease, which affects many organs and systems, but mainly
attacks synovial joints and may lead to cartilage destruc-
tion and deformation, resulting in chronic pain, severe
disability and increased mortality. Despite recent progress,
our understanding of the etiology and pathophysiology
of RA is still far from complete. Currently, there are
numerous animal models of RA-like disease, including K/
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reproduction in any medium, provided the orarthritis, SKG mutant, lpr, and IL-1Ra−/− mice [1], each of
which mirror various aspects of RA. However, a common
weakness of all models is the reliance on an entirely
murine-based immune response to inflammation. As such,
there have been instances where these models have led to
contradictory results in therapeutic efficacy studies as
compared to RA patients. For example, previous studies
that examined the effect of biologic therapy in murine sys-
tems of RA-like disease have noted that inhibiting IL-1
provided suppression or complete amelioration of arth-
ritis. However, anti-IL-1 therapy, although very successful
in treating autoinflammatory syndromes and systemic
juvenile idiopathic arthritis [2], has limited efficacy in RA
patients. One of the closest murine models to human RAl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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DRβ1*0401 (DR4) gene, which develops an RA-like dis-
ease following stimulation with collagen or citrullinated
peptides [3]. While this model represents a tremendous
discovery as the initiation of the disease is mediated by the
expression of the share epitope, it still retains the limita-
tions of all the previous models of RA-like disease, namely
that the inflammation is driven by the murine immune
system that ectopically express the shared epitope. The
central reason for discrepancies between animal models
and patients may be attributed to differences between
human and murine immune systems. These differences
affect both innate and adaptive immunity, including the
balance of leukocyte subsets, defensins, toll-like receptors
(TLR), inducible NO synthase, NK inhibitory receptor
families Ly49 and KIR, FcR, Ig subsets, B cell (BLNK, Btk,
and λ5) and T cell (ZAP70 and common γ-chain) signaling
pathway components, Thy-1, γδT cells, cytokines and
cytokine receptors, Th1/Th2 differentiation, costimulatory
molecule expression and function, antigen presenting
function of endothelial cells, and chemokine and chemo-
kine receptor expression [1]. Thus, development of an in-
flammatory arthritis model using human cells would be
useful to understand how the human immune system
responds during the course of inflammatory arthritis, and
may direct the development of future therapies with
improved efficacy as well as selectivity.
Until recently, many attempts to engraft human im-
mune cells into various immunodeficient mice resulted
in poor and short-term engraftment, which was mainly
attributed to residual activity of the host’s immune sys-
tem. To overcome these issues three major improve-
ments were made over the last 15 years. First, was the
generation of SCID (PrkdcScid) mice, which have a muta-
tion in the protein kinase, DNA-activated, catalytic poly-
peptide (Prkdc) gene and thus lack T- or B-cells but still
have high NK-cell activity. These mice were able to sus-
tain a limited and transient engraftment of the human
immune system. A second improvement was the intro-
duction of the SCID mutation into the NOD back-
ground, which has substantially decreased activity of
NK-cells, deficiency in C5, and inability of macrophages
to produce IL-1β in response to stimulation with LPS, as
well as other defects of the innate immune system [4].
Both SCID and NOD-SCID mice have been widely used
to study the engraftment of synovial tissue from RA
patients [5]. One study has even shown short-term re-
constitution of human bone marrow stem cells in an
arthritis model [6]. However, these models either do not
have a functional human immune system and/or support
long-term engraftment of hematopoietic cells. A third
generation of immunodeficient mice have the deletion of
the IL2rγ gene which is also known as the common
cytokine-receptor γ-chain, and is required for IL-2, IL-4,IL-7, IL-9, IL-15 and IL-21 signaling, and its absence
significantly affects functioning of the innate immune
system (such as monocytes and neutrophils) and com-
pletely prevents NK-cell development [4]. The three
immunodeficient mouse strains that employ this
advantage are: BALB/c-Rag2−/− IL2rγ−/−, NOD-Rag1−/−
IL2rγ−/−, and NOD-scid IL2rγnull (the latter is commonly
referred as NSG for NOD scid gamma). The inactivation
of the gamma chain of the IL-2 receptor has dramatic-
ally improved the engraftment of human cells. While the
only cell types that remain in these immunodeficient
mice are neutrophils, monocytes/macrophages, and den-
dritic cells, they are hypofunctional [7], which is evident
by the lack the inflammatory immune response to
bacterial and fungal pathogens [8]. These characteristics
allow not only transfer of human peripheral blood
mononuclear cells (PBMC), but also support long-term
engraftment of human hematopoietic stem cells (HSC).
Over time, engrafted HSC undergo multilineage devel-
opment, resulting in a fully functional human immune
system, including T, B, NK and dendritic cells, as well as
monocytes/macrophages and granulocytes. Human T
cells undergo positive and negative selection in the
thymus (which prevents development of the graft versus
host disease), display a diverse repertoire of T cell recep-
tors, exhibit human leukocyte dependent cytotoxicity,
and produce a delayed type hypersensitivity response.
Mature B-cells expressing functional B-cell receptors are
readily detected as well as circulating IgM and IgG.
Macrophage and dendritic cell production of cytokines
and chemokines and presentation of antigens to T-cells
have all been demonstrated in the humanized mouse
[4,9]. This humanized mouse model helped the progres-
sion of studies on human-specific infectious diseases,
such as HIV, Dengue virus and Salmonella typhi for
which animals are not susceptible [4,9]. Moreover, it also
uncovered pathophysiological mechanisms involved in
sepsis in humans [10]. However, the tremendous poten-
tial of this model to study human autoimmunity has
been minimally explored. Here, we developed a unique
humanized mouse model for acute inflammatory arth-
ritis. The major strength of this model is the ability to
compare and contrast the activity of human immune
cells prior to and during the course of inflamma-




NOD-scid IL2rγnull (NSG) mice (Jackson Laboratory)
were maintained at the barrier and specific pathogen-
free facility at the Center for Comparative Medicine at
Northwestern University. The Institutional Animal Care
and Use and IRB committees (STU00024421) at
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Humanized mice were generated using a modified
protocol as described [11]. Twelve to twenty-four hour
NSG pups were irradiated with 100 cGy and then recon-
stituted with 0.5x105 human CD34+ hematopoietic stem
cells (HSC) (Lonza, NJ) via intrahepatic injection. Alter-
natively, irradiated newborn pups were injected with
1x105 CD34+ cells isolated from peripheral blood of
healthy adult volunteers using CD34+ microbeads
(Miltenyi, CA). Peripheral blood from humanized mice
was obtained and analyzed using flow cytometry at the
indicated time points. Reconstitution was considered to
be successful if the number of human CD45+ cells in
peripheral blood was more than 10% by week 10. Peri-
tonitis was induced using aged 4% thioglycollate broth.
Flow cytometry
Peripheral blood, spleen, bone marrow, and peritoneal
cavity were processed as previously described [12]. After
Live/Dead staining with Aqua dye (Invitrogen, CA)
single cell suspensions (~1x106 cells) were stained with a
mixture of fluorochrome-conjugated antibodies against
human CD45 (HI30), human CD4 (RPA-T4), human
CD8 (RPA-T8), human CD14 (M5E2), human CD15
(HI98), human CD19 (HIB19), human CD56 (B159),
human CD68 (eBioY1/82A), mouse CD45 (30-F11),
mouse CD11b (M1/70), and mouse Gr-1 (RB6-8C5)
antibodies. For intracellular staining (human CD68),
cells were fixed in 2% paraformaldehyde and permeabi-
lized in 0.1% saponin. Samples were acquired on a BD
LSR II flow cytometer (BD Biosciences) and compensa-
tion and analyses were performed using FlowJo software
(Treestar Inc, OR).
B cell responses
To evaluate the specific adaptive B cell response of the
human immune system in humanized mice, three 12-
week old humanized mice were challenged with 3 IP
injections of 2 μg of ActHIB vaccine (Aventis Pasteur,
France), performed at 3- and 4- week intervals, respect-
ively. Levels of HIB-specific antibodies were determined
by ELISA (DEMEDITEC Diagnostics Gmbh, Germany).
Immunoglobulin production in a cohort of 5 humanized
mice was assessed using MILLIPLEX MAP Human Im-
munoglobulin Isotyping Kits (Millipore, MA).
Adjuvant-induced arthritis in humanized mice
To induce arthritis in humanized mice, 10 μL of
complete Freund’s adjuvant (CFA) 4 mg/mL (Chondrex,
Redmond, WA) or vehicle (incomplete Freund’s adju-
vant) were injected into the knee joint or into the peri-
articular space around the ankle. Additionally mice were
treated subcutaneously with Etanercept (Enbrel, Amgen,
Thousand Oaks, CA, and Pfizer Inc.) at 0.8 mg/kg onday −2 and day 0 or with PBS. Anti-Gr-1 antibody
(0.25 mg) was administered (IP) on days −1 and 1 to
deplete mouse neutrophils. Arthritis and ankle joint pro-
cessing was performed as previously described [12]. Per-
cent staining, bone damage, and inflammation scores
were assessed by a pathologist (G.K.H.) blinded to the
study [12-17]. Tibio-talar and knee joints of humanized
mice were scored separately for bone erosion, inflamma-
tion, pannus formation and infiltration with specific cell
subsets. The following criteria were used for inflamma-
tion: 0 – normal; 1 – minimal infiltration of inflamma-
tory cells in periarticular tissue; 2 – mild infiltration; 3 –
moderate infiltration, with moderate edema; 4 – marked
infiltration, with marked edema; and 5 – severe infiltra-
tion, with severe edema. Pannus formation was scored
according to the following criteria: 0 – normal; 1 – few
pannus formation at 1 to 2 position; 2 – moderate
pannus formation at 1 to 2 position; 3 – pronounced
pannus formation with accretion to cartilage; 4 –
pronounced pannus formation with cartilage overgrow;
5 – pronounced cartilage destruction due to pannus in-
vasion. Bone erosion was scored according to the follow-
ing criteria: 0 – normal; 1 – Small areas of resorption,
not readily apparent on low magnification, in trabecular
or cortical bone; 2 – More numerous areas of resorp-
tion, not readily apparent on low magnification, in tra-
becular or cortical bone; 3 – Obvious resorption of
trabecular and cortical bone, without full thickness
defects in the cortex; loss of some trabeculae; lesions
apparent on low magnification; 4 – Full thickness
defects in the cortical bone and marked trabecular bone
loss, without distortion of the profile of the remaining
cortical surface; 5 – Full thickness defects in the cortical
bone and marked trabecular bone loss, with distortion
of the profile of the remaining cortical surface.
Statistics
Comparison between experimental and control groups
was performed using Student’s unpaired two-tailed
t-tests or, when appropriate, a Mann–Whitney test.
Results
Generation and characterization of humanized mice
Other groups have previously utilized NSG mice to
examine infectious disease models, but their usefulness
for the study of autoimmune diseases, such as RA, is un-
known. Thus, we applied the NSG mouse model to the
study of inflammatory arthritis. One-day old irradiated
NSG pups were reconstituted with human CD34+ cord
blood stem cells, similar to prior studies [11]. Engraft-
ment was documented using flow cytometry and immu-
nohistochemistry. Multilineage development of human
leukocytes in primary and secondary lymphoid organs
was detected (Figure 1A-D). The percent engraftment
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development, and the survival of reconstituted huma-
nized mice were comparable to previous reports [18,19].
Humanized mice spontaneously produced human
immunoglobulins (Figure 2A) as well as specific IgG in
response to immunization with ActHIB vaccine
(Figure 2B). In contrast to cord blood stem cells, CD34+
stem cells isolated from peripheral blood of healthy
adult volunteers were unable to reconstitute the immune
system of irradiated newborn NSG mice (data not
shown), consistent with a recent report [19]. Innate im-
mune system function in humanized NSG mice was also
investigated using a sterile peritonitis thioglycollate in-
jection model. Human macrophages and neutrophils
were readily detected in the elicited peritoneal cavity
(Figure 2C). Taken together and consistent with previousFigure 1 Multilineage development of the human immune system in
described in the Materials and Methods. Dead cells and debris were exclud
FSC-H dot plots (not shown). (A) Multilineage development in bone marro
lineages were present. (B) Peripheral blood of a 12-week old “humanized”
monocytes (CD14+) and neutrophils (CD15) can be easily identified. (C) Sp
CD19 B cells, macrophages (CD19-CD68+) and NK cells (CD56+) are shown
CD8, B cell marker, CD20, and macrophage marker, CD68, in the spleen of
representative of >20 mice.studies [19-21], these data indicate that both innate and
adaptive immunity are functional in humanized mice.
Treatment with the TNF inhibitor Etanercept decreases
the severity of CFA-induced arthritis
A well-established model of inflammatory arthritis in
mice is the adjuvant-induced arthritis model [22]. The
applicability for this model as a representative system for
human cells in the joint was examined. Injection of
complete Freund’s adjuvant (CFA) resulted in the devel-
opment of clinical and histological arthritis, as evidenced
by the presence of swelling, erythema, decreased func-
tion, infiltration of immune cells, and signs of bone
erosion (Figure 3A). In contrast, injection of incomplete
Freund’s adjuvant resulted in much less ankle swelling,
erythema and infiltration (data not shown). Sincehumanized mice. Samples were prepared for flow cytometry as
ed on FSC-A vs. SSC-A dot plot, doublets were excluded on FSC-A vs.
w of a 12-week old humanized mouse. Both myeloid and lymphoid
mouse. Mature forms of B cells (CD19+), CD4 and CD8 T cells,
leen of a 12-week old “humanized” mouse: CD4+ and CD8+ T cells,
. (D) Immunohistochemical staining for human T cell markers, CD4 and
12-week old humanized mouse. Magnification 20x. Data are
Figure 2 Characterization of the humanized mouse. (A) Spontaneous production of immunoglobulins by 16-week old “humanized” mice.
Serum from a non-reconstituted NSG mouse was used as a negative control. (B) Production of the anti-HIB immunoglobulin 4 weeks after the
third immunization with Act-HIB. (C) Human immune cells were found in the peritoneal cavity 72 hours after intraperitoneal injection of
thioglycollate. All mature cell types, including T and B cells and macrophages were present.
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and to eliminate the possibility that murine neutrophils
were contributing to the development of arthritis in
NSG mice injected with CFA, anti-Gr-1 antibodies were
administered to reconstituted humanized mice. Pretreat-
ment with anti-Gr-1 antibody eliminated virtually all-
murine neutrophils in blood (Additional file 1: Figure S1)
and tissues (data not shown), but had no effect on the de-
velopment of arthritis. This finding suggests that human
cells were responsible for the development of arthritis in
these animals.
To investigate whether the humanized mouse model
might be suitable for testing therapeutics effective in
RA, reconstituted humanized mice were treated with the
TNF inhibitor Etanercept prior to the initiation of CFA-
induced arthritis. TNF inhibition was chosen, as this
agent is the most common and effective biologic therapy
for RA patients. Humanized mice were randomly
assigned to treatment (Etanercept) or control (PBS)
groups. Groups did not differ in terms of age, sex or per-
centage of human CD45+ cells in peripheral blood.
Treatment with Etanercept decreased histological scores
for pannus formation by 2.3-fold (p = 0.0306), inflamma-
tion by 2.0 fold (p = 0.0008), and bone erosion by 2.7-
fold (p = 0.071) as compared to PBS-treated mice
(Figure 3B). The number of CD45+ human cells was also
reduced by 2.3-fold (p = 0.0037) in the joints of
Etanercept-treated mice, compared to control arthritic
mice (Figure 3C, D). In contrast, there was no difference
in the number of mouse CD45+ cells in the joint be-
tween the groups (Figure 3C, D). Further, the infiltration
by human neutrophils and lymphocytes was reduced by
4.0-fold (p = 0.048) and 1.8-fold (p = 0.009) respectively
in Etanercept-treated mice, compared to control arthriticmice (Figure 3C, D). Although not significant,
Etanercept-treated animals had slightly increased num-
ber of human CD68-positive cells ( p = 0.2238) and
but had significantly increased number of mouse F4/80-
positive cells (61.5 vs. 38.56, p = 0.001). Our data demon-
strate that in this murine model, human cells cause
erosive, inflammatory arthritis that can then be amelio-
rated by a TNF-α inhibitor, which is the first-line
biologic therapy for RA. Thus, we have proof-of-concept
that this model may be used to study the activities of
human immune cells in inflammatory arthritis, at prede-
termined time points, and in response to various thera-
peutics. Such controlled scrutiny of the human immune
response to inflammatory arthritis has not been feasible
until now.
Discussion
Over the past several years, multiple editorials and
reviews on the current state of immunology research
have now suggested a need to refocus on human, and
not mouse, immunology [1,23,24]. Some fundamental
differences between murine and human immune systems
impede the translation of basic science findings to the
bedside. For example, multiple genes and proteins that
are present in humans do not have direct homologs in
mice and vice versa [25]. Indeed, recent comparison of
gene expression profiles between human and mouse
monocytes, which are critical in the pathogenesis of RA,
revealed significant differences, including CD36, CD9,
CXCR4, TREM-1, IL-1, NOS, arginase, and PPARγ
[1,24]. These studies showed strikingly different patterns
of receptors involved in the uptake of phagocytic cargo,
and production of reactive oxygen species and IL-1
between human and mouse monocyte subsets.
Figure 3 Histopathological changes in joints of humanized mice 7 days after the initiation of the CFA-induced arthritis. (A) H&E staining
showing CFA-induced infiltration of the soft tissues of humanized mice treated with Etanercept (left) and PBS (right), magnification 20x.
SL = synovial lining. Arrow denotes invasion site. (B) Histopathological scores for pannus formation, inflammation, and bone erosion in
CFA-treated mice. (C) Immunohistochemistry for human CD45, human CD68, mouse CD45, and mouse F4/80 in humanized mice treated with
PBS (upper row) and Etanercept (lower row). Magnification 40x. (D) Immunohistopathological scores for infiltration of human CD45+ cells, human
CD68+ cells, mouse CD45+ cells, mouse F4/80+ cells, neutrophils, and lymphocytes in humanized mice treated with PBS or Etanercept. Data
represents 5 (Etanercept) and 3 (PBS) mice/group.
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mouse immune systems include the ratio of leukocyte
subsets, expression of Toll-like receptors 2, 3, 9 and 10,
as well as signaling components in B and T cells
[1,25,26]. Thus, the differences between human and
mouse leukocyte activity in response to inflammation
may slow the advancement of research in the field of
autoimmunity. Overcoming these obstacles will acceler-
ate the pace of novel discoveries in disease pathogenesis
and therapeutic targets. Notably, one model that has
been suggested to be reminiscent of human RA is the
human HLA-DR4 transgenic mouse. In this model all
murine antigen-presenting cells express the human HLA
DR4 gene and this allows for presentation of human
epitopes such as citrullinated peptides, which leads to
inflammatory arthritis development. This model is a
great step forward for understanding the role that the
shared epitope plays in the development of RA-like
disease. Nonetheless, the antigen presenting cells, the T-
cells, and all leukocytes originate from the mouse, which
function differently than humans. Future studies may
combine the HLA-DR4 transgenic mouse model and the
humanize mouse model to bring together the strengths
of both systems for studying RA-like disease. A recent
study accomplished a similar task and crossed the
NODShi-scidIL-2γR−/− (NOG) mice with mice that
ectopically express human HLA gene to understand
lymphocyte immune responses [27].
Development of the systemic model of rheumatoid
arthritis in humanized mouse is the ultimate goal [28].
This ideal model would utilize hematopoietic cells
derived from patients with rheumatoid arthritis and
should be driven by clinically relevant immune response
(i.e. to collagen or citrullinated peptides). However, this
would have to occur without using peripheral blood
stem cells as we have observed that these stem cells are
not sufficient to reconstitute the immune system. Thus,
other sources of stem cells such as induced pluripotent
stem cells or cord blood stem cells from patients who
have RA as the offspring may carry similar genetic pre-
dispositions for RA. While currently available NSG
mouse provides much better engraftment and develop-
ment of the human immune system than previous mod-
els (SCID or NOD-SCID mice), the functionality of the
human immune system in humanized mouse is still lim-
ited. In particular development of B cells and production
of antibodies in response to immunization are impaired
[29]. Deficiency of complement C5 component, which
NSG mice have due to their NOD background, leads to
decreased activity of the residual mouse immune system
[8], however, on the other hand, it may decrease
response of the human immune system as well. Recently,
improved immunodeficient NSG mouse strains were
generated and support better development of myeloidand lymphoid cells [30-34], allowing for development of
the humanized mouse model that may closely reproduce
rheumatoid arthritis. While these strains are not widely
available we have chosen local injection of the CFA as a
simple and robust and way to assess usefulness of the
currently available humanized mouse model to test anti-
arthritis therapy.
Here, we have generated a humanized mouse by trans-
ferring isolated cord blood stem cells into irradiated
one-day old NSG mice. These mice develop a fully func-
tional human immune system that is capable of innate
and adaptive immune responses. Furthermore, the
human leukocytes are able to traffic and extravasate into
primary and secondary lymphoid organs and to inflamed
tissues. While other animal models of RA have exam-
ined the role of IL-1, we chose to focus on TNF-α inhib-
ition, as anti-IL-1 therapy has overall inferior clinical
efficacy compared to TNF-α inhibitors in RA patients.
Experimental inflammatory arthritis develops in this
mouse and is suppressed by a TNF-α inhibitor and is
associated with reduction of human but not mouse leu-
kocytes in the joint (Figure 3). However, there was no ef-
fect on macrophage numbers, which may be due to the
time of harvesting the joints or that these macrophage
have an altered phenotype and become responsible for
the resolution phase of the disease. Future studies will
be required to further understand the role that the
human macrophages play in this model. Interestingly,
previous studies have shown that anti-IL-1 therapy is
successful at ameliorating AIA [35,36], while anti-TNF
therapy has yielded conflicting results in the AIA model
[36-39]. Since TNF inhibition is considered to be the
first-line biologic therapy, the fact that human cells re-
spond better than the murine cells indicates that the
humanized mouse system has the potential to replicate
the responses that occur in patients. While the acute in-
flammatory arthritis that results from injecting adjuvant
into the joints of mice does not entirely reflect the com-
plexities of the adaptive and innate immune responses
that occur in RA, additional studies using other models
of RA-like disease will provide more information on the
suitability of this new model. Further, future studies will
aim at recreating a spontaneous arthritis using stem cells
from RA patients carrying HLA alleles strongly asso-
ciated with the high risk of RA. However, the fact that
we have shown recruitment of engrafted human cells,
their physiologic response to adjuvant in the form of in-
flammatory arthritis, and reduction of disease burden
with TNF-α inhibition that directly correlates with
decrease in numbers from the joint, suggests the feasibil-
ity of performing such experiments using genetically
susceptible samples from patients in the future.
The humanized mouse has already had a profound
impact on infectious disease research including HIV
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studies utilized the potential of the humanized mouse
to understand the pathogenesis of autoimmune
disease, such as type 1 diabetes [40]. Brehm and col-
leagues showed that human islet cells were capable of
restoring normal glycemic levels in NSG-Akita mice
and that human leukocytes derived from stem cells
were capable of rejecting human islet allographs [41].
Further, injection of peripheral blood mononuclear
cells from SLE patients into BalbRag2−/−IL2rγnull mice
led to autoantibody production and increased mortal-
ity as compared to injection of cells from control
patients [42]. More recently, Kuwana and colleagues
reported spontaneous development of erosive arthritis
in humanized mice infected with Epstein-Barr virus
[43], which was mostly T cell driven with very few
macrophages and B cells involved in the joint path-
ology. These data together with our findings suggest
that the humanized mouse model may provide a suit-
able system to validate novel therapeutics for auto-
immune disease.
Conclusions
The goal of this manuscript is to provide proof-of-
concept that human immune cells in the mouse sys-
tem will behave in a manner that is reminiscent of
humans. The first step toward developing a model
that is similar to human RA is to demonstrate that
human immune cells in a model of inflammatory
arthritis behave in a manner that mirrors patients.
Herein we have determined that the humanized
mouse model of acute inflammatory arthritis permits
the trafficking of human leukocytes to the joint, per-
haps using mouse adhesion receptors on the endothe-
lial surface [44], and produce pro-inflammatory
molecules while in the joint. Moreover, treatment
with the first-line biologic used in RA patients ame-
liorates arthritis and correlates with a reduction in
human leukocytes but not mouse leukocytes in the
joint. Thus, we propose a novel, humanized mouse
model to dissect the intricacies of human immune
cell activities in the initiation, propagation, and reso-
lution of inflammatory arthritis.Additional file
Additional file 1: Figure S1. Depletion of murine neutrophils with
anti-Gr-1 antibody. Peripheral blood from humanized mouse was
collected before and 24 hours after IP injection of 0.25 mg of anti-Gr-1
antibody (clone RB6-8C5) and analyzed by flow cytometry. After gating
out debris and doublets, human and mouse cells were identified as
positive for human CD45 and mouse CD45 correspondingly. Mouse
neutrophils (N) were identified as CD11b+Gr-1hiSSChi and monocytes (M)
as CD11b+Gr-1int/lowSSClow. Numbers on the contour plots indicate
percentage of the parent population.Abbreviations
AIA, Adjuvant-induced arthritis; CFA, Complete Freund’s adjuvant;
HSC, Hematopoietic stem cells; IP, Intraperitoneal; NSG, NOD-scid IL2rγnull;
PBS, Phosphate buffered saline; RA, Rheumatoid arthritis; TLR, Toll-like
receptor.
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